Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 389

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Global burden of lung cancer in 2022 and projections to 2050: Incidence and mortality estimates from GLOBOCAN

Open access
Zhou, Jialin, Xu, Ying, Liu, Jianmin, Feng, Lili, Yu, Jinming, Chen, Dawei·2024·Cancer Epidemiology

Abstract

BACKGROUND: Lung cancer continues to pose a serious global public health challenge. Timely evidence on the global epidemiological profile of the disease is crucial to facilitate the implementation to lung cancer control efforts. This study provides updated global estimates for lung cancer incidence and mortality in 2022, along with projections for new cases and deaths up to 2050. METHODS: In the population-based study, we extracted data about lung cancer new cases and deaths from GLOBOCAN 2022 database across 185 countries or territories. We analyzed age-standardized rates by sex, country, region, and human development index (HDI). Projected new cases and deaths for 2050 were estimated using global demographic projections. RESULTS: In 2022, lung cancer stood as the most frequently diagnosed cancer and the primary cause of cancer-related deaths on a global scale with approximately 2.48 million new cases and 1.8 million deaths, respectively. The incidence and mortality rates of lung cancer exhibited disparities in sex and world regions. Furthermore, incidence and mortality rates increasing as HDI increased. If the incidence and mortality rates remain stable as in 2022, the burden of lung cancer is projected to increase to 4·62 million new cases and 3·55 million deaths by 2050. CONCLUSIONS: Lung cancer is the predominant form of cancer and the foremost contributor to cancer-related mortality in 2022 with notable geographical, sex, and socioeconomic disparities.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.canep.2024.102693

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Research works printed but not linked: 5

  1. Duma, 2023, Disparities in lung cancer, J. Natl. Med. Assoc., 115
  2. Boffetta, 2001, Incidence of lung cancer in a large cohort of non-smoking men from Sweden, Int. J. Cancer, 94, 591, 10.1002/ijc.1507 · doi:10.1002/ijc.1507
  3. Bao, 2024, LDCT screening results among eligible and ineligible screening candidates in preventive health check-ups population: a real world study in West China, Sci. Rep., 14, 4848, 10.1038/s41598-024-55475-x · doi:10.1038/s41598-024-55475-x
  4. Wu, 2023, Optimizing lung cancer screening with risk prediction: current challenges and the emerging role of biomarkers, J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol., 41, 4341, 10.1200/JCO.23.01060 · doi:10.1200/jco.23.01060
  5. Pinsky, 2021, Potential disparities by sex and race or ethnicity in lung cancer screening eligibility rates, Chest, 160, 341, 10.1016/j.chest.2021.01.070 · doi:10.1016/j.chest.2021.01.070

Cited by

See all 389

Metadata

Authors
Zhou, J., Xu, Y., Liu, J., Feng, L., Yu, J., & Chen, D.
Venue
Cancer Epidemiology
Publisher
Elsevier BV
Published
2024-12
Volume
93
Pages
102693
ISSN
1877-7821 (ISSN-L)
OpenAlex
W4404337253
Cited by
389
References
49
FWCI
59.55
Type
journal article
Language
en
Open access
hybrid
Licence
Funders
  • National Natural Science Foundation of China (8203000516)
  • Shandong Province Natural Science Foundation (ZR2023ZD26)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Global burden of lung cancer in 2022 and projections to 2050: Incidence and mortality estimates from GLOBOCAN. https://app.cochat.ai/papers/10.1016/j.canep.2024.102693
The paper
Zhou, J., Xu, Y., Liu, J., Feng, L., Yu, J., & Chen, D. (2024). Global burden of lung cancer in 2022 and projections to 2050: Incidence and mortality estimates from GLOBOCAN. Cancer Epidemiology. https://doi.org/10.1016/j.canep.2024.102693

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.